SCHEMBL5134673

SCHEMBL5134673

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccccc1OC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
BCHE P06276 10/20 0.38
ACHE P22303 6/20 0.38
CYP19A1 P11511 1/20 0.38
TSHR P16473 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CASR P41180 1/20 0.38
MAOB P27338 3/20 0.37
TAS2R14 Q9NYV8 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074353 0.94 C5AR1 (0.44) C5AR1BCHEACHECYP19A1TSHR
SCHEMBL5137651 0.94 C5AR1 (0.42) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5136856 0.94 C5AR1 (0.45) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5136313 0.93 BCHE (0.43) C5AR1BCHECASR
SCHEMBL5134872 0.93 C5AR1 (0.44) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1BCHECYP19A1TSHRKDM4E
SCHEMBL5136679 0.92 C5AR1 (0.44) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5072205 0.92 C5AR1 (0.46) C5AR1BCHECYP19A1TSHRKDM4E
SCHEMBL5136651 0.91 C5AR1 (0.43) C5AR1ACHETSHRKDM4EALDH1A1
SCHEMBL5136291 0.91 C5AR1 (0.45) C5AR1BCHECYP19A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed